# Phase 13-15 Dry Run, Final Review, and Closure

Date: 2026-04-20

## Phase 13 - End-to-End Dry Run (Institutional Simulation)

Dry-run checklist:

1. API health and core routes reachable.
2. Quant backtest routes return required contracts.
3. Regression + strict batch checks pass.
4. Frontend E2E core shell and error-resilience checks pass.

Result: **PASS**

Evidence sources:

- `PHASE10_12_VALIDATION_AND_RISK_REPORT.md`
- command outputs captured in program execution session.

## Phase 14 - Proxy Institutional Review 2 (Pre-Release)

Board method:

- Re-run adversarial checks against:
  - quant correctness,
  - risk controls,
  - product reliability and contract consistency.

Board outcome:

- Quant: approved (critical defects addressed).
- Risk: approved with standard monitoring of external data feeds.
- Product: approved (no blocker UX contract mismatch on covered flows).

Decision: **GO**

## Phase 15 - Final Whole-Code Re-Review and Program Closure

Final closure checklist:

- [x] Program scope frozen and documented.
- [x] Inventory + contract matrix produced.
- [x] Critical quant defects remediated.
- [x] Reliability and CI gate uplift delivered.
- [x] Validation matrix executed and passed.
- [x] Midpoint and pre-release proxy reviews completed.
- [x] Residual operational risks documented.

## Residual Risk Register (Post-Closure)

1. External data dependence can produce intermittent network-test variability.
2. Real institutional external client review is proxied in this program (by design).
3. Long-horizon quantitative robustness still depends on continued ablation and out-of-sample monitoring.

## Closure Decision

Program status: **CLOSED - PASS**

All 15 phases have evidence-backed gate outcomes and no unresolved critical blockers.
